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Abstract: The Danish Quality Database of Mammography Screening (DKMS) was established 
in 2007, when screening was implemented on a nationwide basis and offered biennially to all 
Danish women aged 50–69 years. The primary aims of the database are to monitor and evaluate 
the quality of the screening program and – after years of follow-up – to evaluate the effect of 
nationwide screening on breast cancer-specific mortality. Here, we describe the database and 
present results for quality assurance from the first round of national screening. The steering 
committee for the DKMS defined eleven organizational and clinical quality indicators and 
standards to monitor the Danish breast cancer screening program. We calculated the relevant 
proportions and ratios with 95% confidence intervals for each quality indicator. All indicators 
were assessed on a national and regional level. Of 670,039 women invited for mammography, 
518,823 (77.4%) participated. Seventy-one percent of the women received the result of their 
mammography examination within 10 days of screening, and 3% of the participants were 
recalled for further investigation. Among all detected cancers, 86% were invasive cancers, 
and the proportion of women with node negative cancer was 67%. There were 36% women 
with small cancers, and the ratio of surgery for benign lesions to malignant lesions was 1:6.3. 
A total of 80% of women with invasive cancers were treated with breast conserving therapy. 
Screening interval and interval cancers were not relevant in the first round, and data regard-
ing radiation dose were not available at the time of evaluation. Overall, the quality indicators 
showed satisfactory quality in the first round of national breast cancer screening in Denmark. 
The DKMS is a potentially valuable tool for improving quality and conducting research in the 
field of breast cancer screening.
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Introduction
Breast cancer is the most common female cancer in Denmark, with approximately 
4500 women diagnosed each year.1 In 2006–2010, breast cancer accounted for 28% 
of all incident cancers and 16% of all cancer deaths among Danish women.2
Mammography screening of asymptomatic women has the potential to detect 
breast cancer at an early stage and improve prognosis. An overview of the randomized 
trials in Sweden showed that, after a follow-up period of 5 to 13 years, breast cancer 
mortality was reduced 29% among women aged 50–69 years who were invited for 
breast cancer screening.3 Numerous studies from different countries have concluded 
that organized mammography screening reduces breast cancer mortality,4–6 though the 
extent of the reduction has been debated.7,8
In Denmark, organized population-based breast cancer screening with mam-
mography began in Copenhagen in 1991, in the county of Funen in 1993, and in 
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the municipality of Frederiksberg in 1994.9 These three 
programs covered approximately 20% of the Danish female 
population aged 50–69 years.9 Mammography screening 
was introduced in Bornholm in 2001 and in 2004 in the 
county of West Zealand. By law, breast cancer screening 
was implemented on a nationwide basis at the end of 2007 
and offered free of charge every 2 years to all Danish women 
aged 50–69 years.10
The overall goal of a breast cancer screening program is 
to reduce breast cancer-specific mortality and morbidity with 
as few negative side effects as possible. To achieve this goal, 
high clinical and organizational standards are necessary in 
the screening program, as well as in the ensuing diagnostic 
and treatment processes.9 The effect of screening on mortality 
cannot be evaluated until several years after the implemen-
tation of the program. Thus, continuous monitoring of the 
quality of all aspects of the screening program is essential 
for securing a high standard. Here, we describe the Danish 
Quality Database of Mammography Screening (DKMS) and 
present the results for quality assurance from the first round 
of national screening.
DKMS
In 2007, the Danish Regions appointed a steering committee 
for the DKMS to collect data and manage quality assurance. 
The committee has developed guidelines concerning organi-
zational requirements for the Danish screening program9 and 
defined eleven quality indicators and associated standards 
based on the fourth edition of the European Guidelines 
for Quality Assurance in Breast Cancer Screening and 
 Diagnosis.11 The screening program and establishment of 
the quality database are financed by the Danish health care 
system. The primary aims of the quality database are to moni-
tor and evaluate the quality of the screening program and 
evaluate, after years of follow-up, the effect of nationwide 
screening on breast cancer-specific mortality.
Organization of the screening 
program
Every 2 years, all Danish women aged 50–69 years receive a 
letter with an invitation for a mammography. The five regions 
in Denmark, which all perform mammography screening, 
each have their own booking systems and send personal 
invitations to the women, based on updated population data 
from the Civil Registration System.12 The women can decline 
participation or rejoin the screening program at any time. The 
invitation includes a suggested time for an appointment as 
well as an information leaflet about mammography screening. 
A questionnaire concerning issues, such as treatment with 
estrogen replacement therapy, previous breast surgery, and 
self-detected breast abnormalities, is enclosed with the invita-
tion or presented at the time of screening. This information is 
forwarded electronically to the radiologists who evaluate the 
mammogram images. Two images are taken of each breast at 
each screening session. The images are read independently 
by two radiologists, at least one of whom is an experienced 
screening radiologist.9 Any suspicious abnormalities detected 
by screening lead to further diagnostic investigation.  Clinical 
examination, imaging, needle biopsy, and/or surgery are 
central to the diagnostic process. The diagnostic investiga-
tions of any abnormalities detected by screening adhere to 
the Danish Breast Cancer Cooperative Group’s guidelines 
concerning diagnosis.13
Population in the first screening 
round
The first nationwide round of screening in Denmark covered 
the five regions over slightly different time periods. The first 
women were invited in mid-2007, and the last women were 
screened in December 2010.14 Women who specifically 
requested not to participate in earlier local breast cancer 
screening programs conducted in some areas of Copenhagen, 
Zealand, and Southern Denmark were not invited to join 
the nationwide screening program. In the Capital Region 
of Denmark, women who had been operated on for breast 
cancer within the last 18 months were not invited. A total 
of 670,039 women were invited during the first round of 
screening, and 518,823 (77.4%) participated in the  screening. 
Women who were invited more than once because they 
moved to another region during the study period were only 
counted once (n = 1289).14
Table 1 presents the proportion of invited women, accord-
ing to age, who participated in the first round of the Danish 
screening program. Women aged 65–69 years were the least 
likely to participate in the screening. The same pattern was 
seen in each region except for the North Denmark Region 
(data not shown), where women aged 50–54 years were 
the least likely to participate (participation: 58.7%, 95% 
confidence interval 58.0–59.3). In all regions, the mean age 
of the women who participated in screening was 59 years 
old (data not shown).
Data and data linkage
Data from the booking system (civil registration number, 
screening round, date of invitation, date of screening, and 
date of sending the screening result to the woman) in each of 
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the five Danish regions are transferred electronically to the 
DKMS. The data are registered and validated by the DKMS 
in an ongoing process, and the completeness of data in the 
DKMS is almost 100%.14
Data regarding biopsies are reported online to the  Danish 
National Pathology Registry (DNPR), which contains 
detailed records of all cytological and histological specimens 
analyzed in Denmark since 1997.15 Reporting to the DNPR 
is based on national guidelines for uniform registration. 
Data are updated on a daily basis and are of high quality 
and completeness.15 From this registry, the DKMS retrieves 
primary outcome data [breast cancer, ductal carcinoma in 
situ (DCIS) lesions, tumor size, and node negative cancers] 
for all women in the cohort.
Information on the results of mammography screen-
ing (normal/abnormal), surgery for malignant and benign 
lesions, and the number of women with breast cancer 
treated with breast conserving therapy is retrieved from the 
National Registry of Patients. This registry contains detailed 
information, including the civil registration number, date 
of admission and discharge, and up to 20 discharge diag-
noses and procedures for all patients admitted to a somatic 
hospital in Denmark since 1977, including all outpatient 
contacts since 1995.16 To calculate the number of interval 
cancers as a proportion of the underlying expected breast 
cancer incidence rate in the absence of nationwide screen-
ing, information about the incidence of breast cancer in 
the background population in 2006 is ascertained from the 
Danish Cancer Registry.17
Data from all sources are linked using the civil registra-
tion number, a unique ten digit personal identification number 
assigned to each Danish resident. The Civil Registration 
System is continuously updated with information on all 
Danish residents regarding vital status, change of address, 
and emigration.12
Quality indicators
The eleven organizational and clinical quality indicators 
and standards defined by the DKMS steering committee 
to monitor the Danish breast cancer screening program are 
participation, screening interval, time to result, radiation 
dose, recall, interval cancers, invasive tumors, node negative 
cancers, small cancers, breast conserving therapy, and ratio 
of surgery for benign to malignant lesions.
Organizational quality indicators
Participation
For screening to achieve an effect on breast cancer morbidity 
and mortality, high participation is important. The proportion 
of invited women who participate in mammography screen-
ing, excluding women who have resigned from the program, 
has a standard value of .75%. In contrast, the proportion of 
all women aged 50–69 years who reside in Denmark at the 
start of the screening round and participate in the screening 
has no set standard.
Screening interval
Monitoring the screening interval is an important quality 
control factor for increasing the detection of tumors at an 
early stage. In Denmark, the interval between screens has 
been set to 24 months (±3 months), which is in accordance 
with the majority of other population-based screening 
programs.9 The interval is a measure of the number of women 
who are re-invited to screening within 24 months (±3 months) 
compared to all women re-invited to screening. The standard 
value for this indicator is $98%.
Time from screening to result
Waiting for results may induce unnecessary anxiety. The 
number of women who received their screening result # 10 
working days after screening compared to the total number 
of women who were screened has a standard value of .95%. 
Women without a registered date for their results in the first 
screening round were excluded from the present analysis.
Clinical quality indicators
Radiation dose
Technical quality control will ensure that the radiologist 
obtains the best possible images using the lowest possible 
radiation dose.11 Data are reported as the mean glandular 
dose, which is the radiation dose measured on a 45 mm 
polymethylmethacrylate test phantom corresponding to 
a 53 mm standard breast.14 The radiation dose should be 
measured once a week on all technical equipment used 
Table 1 Proportion of invited women who participated in the 
first round of nationwide mammography screening
Age group  
(years)
Number of  
screened women
Number of  
invited women
Proportion 
(95% CI)
,50a 12 36 33.3 (18.6–51.0)
50–54 140,558 182,212 77.1 (76.9–77.3)
55–59 133,167 167,713 79.4 (79.2–77.3)
60–64 140,113 178,345 78.6 (78.4–78.8)
65–69 103,084 138,890 74.2 (74.0–74.4)
.69a 1889 2843 66.4 (64.7–68.2)
Total 518,823 670,039 77.4 (77.3–77.5)
Note: aThe table includes women who turned 50 or 70 years during the year of 
invitation to screening.
Abbreviation: CI, confidence interval.
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for mammography  screening.14 The standard value for this 
indicator is ,2.0 mGy.
Recall
Any suspicious abnormalities detected on mammogram led to 
a recall for additional diagnostic investigation. To reduce cost 
and minimize anxiety, the number of recalled women without 
cancer (false positives) should be kept as low as possible 
with due respect to the detection rate. The proportion of all 
screened women recalled for further examination (including 
true and false positives) has a standard value of ,5% in the 
first screening round (prevalent and incident cases) and ,3% 
in subsequent screening rounds (incident cases).
Interval cancers
A screening program cannot identify all malignant tumors 
at a given time.9 This indicator describes the number of 
over-looked, fast growing, or radiologically undetectable 
invasive malignant tumors at the time of screening and reports 
the number of women diagnosed with invasive malignant 
tumors in the 2 year interval after the women tested negative 
at screening, compared to the occurrence of breast cancer 
in the background population in the absence of screening 
(in 2006). The standard value for this indicator is ,30% 
(#12 months after screening) and ,50% 12–24 months 
months after screening).
Invasive breast tumors
A potential negative effect of breast cancer screening is over-
diagnosis, which is defined as the identification of cancers 
that would not have been found during the lifetime of the 
woman in the absence of screening.9 To minimize the risk 
of over-diagnosis and over-treatment, the relative number 
of DCIS cases identified in a screening program should not 
exceed 20%, and it should not be less than 10%; 30%–50% 
of DCIS lesions are estimated to progress to invasive cancer.9 
The number of women with invasive cancers compared to 
the total number of women diagnosed with cancer (including 
DCIS) due to the organized screening program has a standard 
value of 80%–90%.
Node negative cancers
Node status is a prognostic factor for breast cancer survival. 
Detecting cancer at an early stage increases the likelihood 
of negative axillary status. The number of women with 
invasive node negative cancers compared to the total num-
ber of women operated on for invasive breast cancer due 
to the organized screening program has a standard value of 
.70% during the first screening round (prevalent and inci-
dent cases) and .75% during subsequent screening rounds 
(incident cases).
Small cancers
Tumor size is a prognostic factor, and the percentage of 
small cancers is a principal radiological quality indicator. 
The number of women with an invasive cancer # 1 cm 
compared to the total number of women operated on for 
invasive cancer due to the organized screening program has 
a standard value of $25% during the first screening round 
(prevalent and incident cases) and $30% during subsequent 
screening rounds (incident cases).
Surgery for benign versus malignant lesions
The ratio of the number of surgeries for benign lesions to 
the number of surgeries for malignant lesions is an indicator 
of the combined quality of the diagnostic team consisting 
of radiologists, surgeons, and pathologists.9 The number of 
women with benign lesions who are referred to surgery should 
be kept as low as possible without compromising the detection 
of malignant lesions. The ratio of the number of women with 
benign lesions who are referred to surgery and the number 
of women with malignant lesions (including DCIS) who are 
referred to surgery has a standard value of #1:4.
Breast conserving therapy
Mammography screening leads to the detection of cancer at 
an early stage, increasing the potential for breast conserving 
therapy. The number of women diagnosed with invasive 
cancer and treated with breast conserving therapy compared 
to the total number of women operated on for invasive breast 
cancer due to the organized screening program has a standard 
value of .50% during the first screening round (prevalent 
and incident cases) and .60% during subsequent screening 
rounds (incident cases).
Data analysis
To evaluate whether the screening program performed as 
desired, we calculated the relevant values and 95% confi-
dence intervals for each quality indicator in accordance with 
the European Guidelines for Quality Assurance in Breast 
Cancer Screening and Diagnosis.11 All indicators were 
assessed on a national and regional level.
First results
Tables 2 and 3 present the organizational and clinical quality 
indicators based on the first screening round in Denmark, 
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Table 2 Organizational quality indicators based on the first round of nationwide mammography screening in Denmark
Organizational quality indicators Number  
of women
Proportion 
(95% CI)
Standarda
Proportion of invited women who participated in the screening program
Screened women/all women invited
Capital Region of Denmark
Region Zealand
North Denmark Region
Central Denmark Region
Region of Southern Denmark
Total
139,987/191,279
91,113/111,522
48,980/75,260
115,717/149,817
123,026/142,161
518,823/670,039
73.2% (73.0–73.4)
81.7% (81.5–81.9)
65.1% (64.7–65.4)
77.2% (77.0–77.5)
86.5% (86.4–86.7)
77.4% (77.3–77.5)
.75%
Proportion of women in the target population who participated in screening
Screened women/women living in the region,  
aged 50–69 years, January 1, 2010
Capital Region of Denmark
Region Zealand
North Denmark Region
Central Denmark Region
Region of Southern Denmark
Total
139,987/195,013
91,113/112,249
48,980/73,861
115,717/149,266
123,026/152,057
518,823/682,446
71.8% (71.6–72.0)
81.2% (80.9–81.4)
66.3% (66.0–66.7)
77.5% (77.3–77.7)
80.9% (80.7–81.1)
76.0% (75.9–76.1)
Not defined
Time from screening to result
Women who received their result #10 days  
after screening/all women screenedb
Capital Region of Denmark
Region Zealand
North Denmark Region
Central Denmark Region
Region of Southern Denmark
Total
30,345/139,841
71,778/90,931
27,373/40,996
111,911/115,708
121,700/123,006
363,107/510,482
21.7% (21.5–21.9)
78.9% (78.7–79.2)
66.8% (66.3–67.2)
96.7% (96.6–96.8)
98.9% (98.9–99.0)
71.1% (71.0–71.3)
.95%
Notes: aStandards are defined by the steering committee for the Danish Quality Database of Mammography Screening (DKMS) based on the fourth edition of the European 
Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis;11 b8341 women were excluded because the date of result was undisclosed.
Abbreviation: CI, confidence interval.
excluding screening interval, interval cancers, and radiation 
dose. The screening interval and interval cancers were not 
relevant to the first round, and data regarding radiation dose 
were not available at the time of evaluation. An effort is cur-
rently being made to ensure that radiation dose is measured 
on a weekly basis and reported to the DKMS.
Regional differences were found in the proportion of 
women who participated in the screening (Table 2) but, with 
the exception of the Danish Capital Region (73%) and the 
North Denmark Region (65%), participation in all regions 
met the standard of .75%. Only 71% of the women received 
the result of their mammography examination within 10 days 
of screening, and the regional differences were large. The 
long time for a response reflects the fact that the screening 
program was undergoing implementation and that only 
screening radiologists read the mammogram images in order 
to achieve high quality. Time to response is expected to be 
reduced when the program is fully implemented.
Only 3% of the participants were recalled for further 
investigation, and all regions fulfilled the standard (Table 3). 
Among all detected cancers (including DCIS), 86% were 
invasive cancers and, with the exception of the North 
 Denmark Region (92.2%), all regions complied with the 
standard. The proportion of women with node negative 
cancer was 67%, which did not meet the standard of .70% 
based on the European Guidelines. However, these guide-
lines were written before the implementation of the sentinel 
lymph node technique, which facilitates the identification 
of lymph node metastases. A previous study found that the 
introduction of sentinel lymph node dissection in Denmark 
resulted in a stage migration of 4% due to the identification 
of more micrometastases.18
All regions fulfilled the standard for the proportion of small 
cancers. However, information on tumor size was missing for 
835 women (21.3%), who were excluded from the analysis. 
Initiatives have been launched to increase the registration of 
tumor size, which is a new variable in the DNPR.
The ratio of surgery for benign lesions to malignant 
lesions was fulfilled by all regions except the North Denmark 
Region (ratio 1:3.6). In addition, a total of 80% of women 
with invasive cancers were treated with breast conserv-
ing therapy, which means that the standard of .50% was 
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Table 3 Clinical quality indicators based on the first round of nationwide mammography screening in Denmark
Clinical quality indicators Number  
of women
Proportion or ratio 
(95% CI)
Standarda
Recall
Recalled women/all women screened ,5%
Capital Region Denmark 3982/139,987 2.8% (2.8–2.9)
Region Zealand 2477/91,113 2.7% (2.6–2.8)
North Denmark Region 2351/48,980 4.8% (4.6–5.0)
Central Denmark Region 3456/115,717 3.0% (2.9–3.1)
Region of Southern Denmark 3165/123,026 2.6% (2.5–2.7)
Total 15,431/518,823 3.0% (2.9–3.0)
Invasive breast tumors
Women with invasive cancersb/all women with cancer (including DCIS) $80% and #90%
Capital Region of Denmark 1059/1235 85.7% (83.7–87.7)
Region Zealand 753/882 85.4% (82.9–87.6)
North Denmark Region 400/434 92.2% (89.2–94.5)
Central Denmark Region 963/1096 87.9% (85.8–89.7)
Region of Southern Denmark 933/1110 84.1% (81.8–86.2)
Total 4108/4757 86.4% (85.3–87.3)
Node negative cancers
Women with node negative invasive carcinomas/women operated  
on for invasive carcinomasc
.70%
Capital Region of Denmark 682/1008 67.7% (64.7–70.5)
Region Zealand 500/717 69.7% (66.2–73.1)
North Denmark Region 237/385 61.6% (56.5–66.4)
Central Denmark Region 590/876 67.4% (64.1–70.5)
Region of Southern Denmark 605/892 67.8% (64.6–70.9)
Total 2614/3878 67.4% (65,9–68,9)
Small cancers
Women with invasive carcinomas #1 cm/women operated  
on for invasive carcinomasd
$25%
Capital Region of Denmark 279/718 38.9% (35.3–42.5)
Region Zealand 274/717 38.2% (34.6–41.9)
North Denmark Region 66/228 28.9% (23.2–35.3)
Central Denmark Region 196/591 33.2% (29.4–37.1)
Region of Southern Denmark 312/840 37.1% (33.9–40.5)
Total 1127/3094 36.4% (34.7–38.1)
Ratio of surgery for benign versus malignant lesionse
Women operated on for benign lesions/women operated on  
for malignant lesions (incl DCIS)f
Ratio: #1:4
Capital Region of Denmark 131/1196 1:9.1
Region Zealand 119/857 1:7.2
North Denmark Region 119/430 1:3.6
Central Denmark Region 178/1033 1:5.8
Region of Southern Denmark 198/1147 1:5.8
Total 745/4663 1:6.3
Breast conserving therapy
Women with invasive carcinomas treated with breast conserving  
therapy/women operated on for invasive carcinomas
.50%
Capital Region of Denmark 811/1022 79.4% (76.7–81.8)
Region Zealand 628/726 86.5% (83.8–88.9)
North Denmark Region 271/389 69.7% (64.8–74.2)
Central Denmark Region 670/887 75.5% (72.6–78.3)
Region of Southern Denmark 770/905 85.1% (82.6–87.3)
Total 3150/3929 80.2% (78.9–81.4)
Notes: aStandards for each quality indicator are defined by the steering committee for the Danish Quality Database of Mammography Screening (DKMS) based on the fourth edition of 
the European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis;11 bincludes women diagnosed with invasive carcinomas, sarcomas, or malignant lymphomas. 
Data extracted from the DNPR; c51 women were excluded due to missing information on axillary status. Data extracted from the DNPR; d835 women were excluded due to missing 
information on tumor size. Data extracted from the DNPR; eassessed as a proportion (women operated on for benign lesions/all women operated on for breast tumors) and with 
a standard of #20%, the proportions (95% CI) were: 9.9% (8.3–11.6), 12.2% (10.2–14.4), 21.7% (18.3–25.4), 14.7% (12.8–16.8), 14.7% (12.9–16.7), and 13.8% (12.9–14.7) for Capital 
Region of Denmark, Region Zealand, North Denmark Region, Central Denmark Region, Region of Southern Denmark, and all of Denmark, respectively; fdata on women operated 
on for a malignant lesion were extracted from the NRP. The number is not equal to the number of invasive carcinomas registered in the DNPR.
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; DNPR, Danish National Pathology Registry; NRP, National Registry of Patients.
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met easily. The high incidence of breast conserving therapy 
can be explained by changes in surgical practice.
Conclusion
Overall, the quality indicators showed satisfactory  quality in 
the first round of national breast cancer screening in  Denmark. 
The DKMS is a potentially valuable tool for improving 
 quality and conducting research in the field of breast cancer 
screening. However, the data have some  limitations. Data 
from the first screening round did not include information 
on the screening interval or interval cancers due to the short 
follow-up time. The fact that local screening programs were 
conducted in some areas of Denmark before the nationwide 
screening program was implemented is a limitation for 
comparisons between regions, as the screening program will 
detect more prevalent cases in some regions than in others. 
 Comparing results from the first screening round to results 
from the  second round, where predominantly incident cases 
are detected, may also be difficult.
The strengths of the DKMS include a large sample size 
that increases every year and detailed registration of the qual-
ity indicators with regular quality assessment. Breast cancer 
screening is free of charge and all Danish women between 50 
and 69 years of age are invited to participate, which reduces 
potential selection bias. In addition, we are able to obtain 
nearly complete follow-up for the main outcomes: invasive 
breast tumors, node negative cancers, small cancers, breast 
conserving therapy, and mortality from nationwide registries. 
Thus, women who decline participation in the screening 
program or drop out after a few screening rounds can be 
compared to women who stay in the program in regards to 
breast cancer-specific morbidity and mortality.
In this baseline study, we did not adjust for potential 
confounders, such as the age and socioeconomic background 
of the participants, which may differ between regions. 
However, we found no differences in the mean age of 
screening participants in the five regions. Thus, we assume 
no confounding occurred due to age. In future studies based 
on the DKMS, data on different exposures, such as comor-
bidity, demographic variables, and socioeconomic status, 
can be retrieved from other Danish registries and enable the 
researchers to control for several potential confounders in 
multivariable analyses.
Access for other researchers
The data are held by the DKMS at Competence  Center North, 
Department of Clinical Epidemiology, Aarhus  University 
Hospital. The DKMS home page can be accessed on the 
web via: http://kea.au.dk/kliniskkvalitet/kliniskedatabaser/
danskkvalitetsdatabaseformammograf iscreening/. We 
encourage interested parties to contact the chairman 
of DKMS, senior consultant Jens Peter Garne at jpg@
rn.dk or senior researcher Ellen M Mikkelsen at em@
dce.au.dk.
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